• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trends in dupilumab persistence among patients with chronic rhinosinusitis with nasal polyps.

作者信息

Stack Taylor J, Zaidi Saif Eddine, Dickerson Theresa A, Pate Virginia, Monk Aurelia S, Benaim Ezer H, Thorp Brian D, Klatt-Cromwell Cristine, Ebert Charles S, Senior Brent A, Kimple Adam J

机构信息

Department of Otolaryngology-Head & Neck Surgery at the University of North Carolina - Chapel Hill.

Department of Epidemiology at the University of North Carolina - Chapel Hill.

出版信息

Rhinol Online. 2024;7(8):69-74. doi: 10.4193/rhinol/24.003. Epub 2024 Jul 9.

DOI:10.4193/rhinol/24.003
PMID:39247706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11378963/
Abstract
摘要

相似文献

1
Trends in dupilumab persistence among patients with chronic rhinosinusitis with nasal polyps.患有鼻息肉的慢性鼻-鼻窦炎患者使用度普利尤单抗的持续治疗趋势。
Rhinol Online. 2024;7(8):69-74. doi: 10.4193/rhinol/24.003. Epub 2024 Jul 9.
2
Biologics for chronic rhinosinusitis.用于慢性鼻-鼻窦炎的生物制剂。
Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD013513. doi: 10.1002/14651858.CD013513.pub2.
3
Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS-24 and SINUS-52 trials.度普利尤单抗在伴鼻息肉的慢性鼻-鼻窦炎中的疗效及生物标志物：3期SINUS-24和SINUS-52试验中，度普利尤单抗治疗对伴鼻息肉的慢性鼻-鼻窦炎患者鼻息肉评分的影响与2型炎症生物标志物之间的关联
Int Forum Allergy Rhinol. 2022 Sep;12(9):1191-1195. doi: 10.1002/alr.22964. Epub 2022 Jan 31.
4
Economic Evaluation of Dupilumab Versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis With Nasal Polyps.度普利尤单抗与鼻内镜手术治疗鼻息肉慢性鼻窦炎的经济学评价
Int Forum Allergy Rhinol. 2022 Jun;12(6):813-820. doi: 10.1002/alr.22936. Epub 2022 Jan 5.
5
Biologics for chronic rhinosinusitis.生物制剂治疗慢性鼻-鼻窦炎。
Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3.
6
Very Rapid Improvement in Extended Nitric Oxide Parameters Is Associated With Clinical and Functional Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps Treated With Dupilumab.度普利尤单抗治疗慢性鼻-鼻窦炎伴鼻息肉患者中，延长的一氧化氮参数的快速改善与临床和功能改善相关。
J Investig Allergol Clin Immunol. 2023 Dec;33(6):457-463. doi: 10.18176/jiaci.0851. Epub 2022 Sep 1.
7
Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?慢性鼻-鼻窦炎伴鼻息肉患者的合并哮喘：度普利尤单抗是否有影响？
BMC Pulm Med. 2023 Jul 18;23(1):266. doi: 10.1186/s12890-023-02556-8.
8
Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.度普利尤单抗治疗伴有鼻息肉的慢性鼻-鼻窦炎的不良反应。病例报告及叙述性综述
Acta Otorhinolaryngol Ital. 2022 Jun;42(3):199-204. doi: 10.14639/0392-100X-N1911.
9
Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.度普利尤单抗治疗与内镜鼻窦手术治疗伴有鼻息肉的慢性鼻-鼻窦炎的疗效比较。
Int Forum Allergy Rhinol. 2022 Aug;12(8):986-995. doi: 10.1002/alr.22951. Epub 2022 Jan 10.
10
The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.度普利尤单抗治疗日本难治性慢性鼻-鼻窦炎伴鼻息肉的疗效。
Laryngoscope. 2021 Jun;131(6):E1770-E1777. doi: 10.1002/lary.29230. Epub 2020 Nov 23.

本文引用的文献

1
Persistent use of dupilumab in adults with asthma or chronic rhinosinusitis with nasal polyps.在患有哮喘或伴有鼻息肉的慢性鼻-鼻窦炎的成人中持续使用度普利尤单抗。
Ann Allergy Asthma Immunol. 2024 Mar;132(3):390-391. doi: 10.1016/j.anai.2023.11.008. Epub 2023 Nov 20.
2
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.度普利尤单抗治疗伴鼻息肉的慢性鼻-鼻窦炎：西西里岛多中心真实世界数据
Am J Otolaryngol. 2024 Jan-Feb;45(1):104106. doi: 10.1016/j.amjoto.2023.104106. Epub 2023 Nov 5.
3
Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience.生物制剂治疗严重非控制型慢性鼻-鼻窦炎伴鼻息肉：一项双中心经验。
Acta Biomed. 2023 Oct 17;94(5):e2023227. doi: 10.23750/abm.v94i5.14745.
4
Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy.度普利尤单抗治疗1年后对慢性鼻-鼻窦炎伴鼻息肉患者有效性和安全性的真实世界证据。
World Allergy Organ J. 2023 May 18;16(5):100780. doi: 10.1016/j.waojou.2023.100780. eCollection 2023 May.
5
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).度普利尤单抗治疗伴有鼻息肉的重度难治性慢性鼻-鼻窦炎（CRSwNP）：一项多中心观察性 IV 期真实世界研究（DUPIREAL）。
Allergy. 2023 Oct;78(10):2669-2683. doi: 10.1111/all.15772. Epub 2023 May 26.
6
EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023.2023 年 EPOS/EUFOREA 关于生物制剂治疗慢性鼻-鼻窦炎伴鼻息肉的适应证和评估的更新。
Rhinology. 2023 Jun 1;61(3):194-202. doi: 10.4193/Rhin22.489.
7
Persistence as a Robust Indicator of Medication Adherence-Related Quality and Performance.坚持是衡量药物依从性相关质量和绩效的有力指标。
Int J Environ Res Public Health. 2021 May 3;18(9):4872. doi: 10.3390/ijerph18094872.
8
Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.度普利尤单抗与内镜鼻窦手术治疗鼻息肉慢性鼻-鼻窦炎的成本效用分析。
Laryngoscope. 2021 Jan;131(1):E26-E33. doi: 10.1002/lary.28648. Epub 2020 Apr 3.
9
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
10
Medication compliance and persistence: terminology and definitions.药物依从性和持续性：术语与定义。
Value Health. 2008 Jan-Feb;11(1):44-7. doi: 10.1111/j.1524-4733.2007.00213.x.